Latest International Intelligence
2022 NRDL Pricing Implications and Access Outcomes
Available On Demand
What are the latest pricing dynamics from the 2022 NRDL update that manufacturers should learn to succeed in China market access? The 2022 National Reimbursement Drug List (NRDL) negotiation has recently published the list of successfully negotiated drugs and their post-negotiation prices. The results indicate an improved access environment for new and high-cost innovative therapies. […]
The German Financial Stabilization of Statutory Health Insurance System Act
Executive Summary: Key Policy Updates AMNOG Rebate Negotiations AMNOG* rebate negotiations will be modified to give the GKV-SV increased powers in the pricing negotiations. HIGH P&MA IMPACT: The new negotiation framework increases the threshold of added benefit required for therapies to receive a premium vs. comparator therapies, specifically by limiting the pricing of ‘No Added […]
Brazil’s Latest Updates to Drug Coverage in the Private Sector: Anticipated Impact and Implications
Executive Summary Introduction Agência Nacional de Saúde Suplementar (ANS) is the Brazilian regulatory agency linked to the Ministry of Health that oversees the private healthcare sector and insurance companies within the country. Key responsibilities of ANS include defining the legislation to regulate private plans and defining the minimum coverage that plans must offer to affiliates, […]
If you have any questions, we’re here to answer them.
We look forward to helping identify solutions for you.